Preview

Педиатрическая фармакология

Расширенный поиск

РЕДКИЙ ПЕРВИЧНЫЙ ИММУНОДЕФИЦИТ — ГИПЕР-IGE-СИНДРОМ: ПРЕЗЕНТАЦИЯ СЛУЧАЯ И ОБЗОР ЛИТЕРАТУРЫ

https://doi.org/10.15690/pf.v10i1.589

Полный текст:

Аннотация

Статья посвящена одной из редких патологий из группы первичных иммунодефицитов — гипер-IgE-синдрому. Авторы представляют клинический случай из собственной практики, а также обзор современных литературных данных по данной болезни. Рассмотрены вопросы наследования, патогенеза, клинических проявлений, а также диагностики гипер-IgE-синдрома. Показаны различия в течении болезни при разных типах наследования — аутосомнодоминантном, аутосомно-рецессивном.

Об авторах

Н. В. Соботюк
Омская государственная медицинская академия, Российская Федерация
доктор медицинских наук, профессор кафедры педиатрии ОмГМА


Е. А. Потрохова
Омская государственная медицинская академия, Российская Федерация


С. А. Голочалова
Омская государственная медицинская академия, Российская Федерация


С. В. Бочанцев
Омская государственная медицинская академия, Российская Федерация


Т. Н. Харламова
Омская государственная медицинская академия, Российская Федерация


Ю. А. Стройлова
Омская государственная медицинская академия, Российская Федерация


Список литературы

1. Steihm E. R., Chin T. W., Haas A., Peerles A. G. Infectious compli cations of the primary immunodeficiencies. Clin Immunol Immunopathol. 1986; 40: 69–86.

2. Ohman S., Johansson S. G. Allergenspecific IgE in atopic dermatitis. Acta Derm Venereol. 1974; 54: 283–290.

3. Schimke L. F., Sawalle-Belohradsky J., Roesler J. Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J of Allergy Clin Immunol. 2010; 126 (3): 611–617.

4. Grimbacher В., Belohradsky B. H., Holland S. M. Immunoglobulin E in primary immunodeficiency diseases. Allergy. 2002; 57: 995–1007.

5. Davis S. D., Schaller J., Wedgwood R. J. Job’s Syndrome. Recurrent, ≪cold≫ staphylococcal abscesses. Lancet. 1966; 1: 1013–1015. 60

6. Buckley R. H., Wray B. B., Belmaker E. Z. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972; 49: 59–70.

7. Hill H. R., Ochs H. D., Quie P. G. et al. Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent ≪cold≫ staphylococcal abscesses. Lancet. 1974; 2: 617–619.

8. Buckley R. H., Becker W. G. Abnormalities in the regulation of human IgE synthesis. Immunol Rev. 1978; 41: 288–314.

9. Hill H. R., Quie P. G. Raised serum IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections. Lancet. 1974; 1: 183–197.

10. Shirafuji Y., Matsuura H., Sato A. Hyperimmunoglobulin E syndrome: a sign of TH1/TH2 imbalance? Eur J Dermatol. 1999; 9: 129–131.

11. Grimbacher B., Holland S. M., Gallin J. I. et al. Hyper IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder. Am J Hum Genet. 1999; 65: 735–744.

12. Renner E. D., Puck J. M., Holland S. M. et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr. 2004; 144: 93–99.

13. Grimbacher B., Holland S. M., Puck J. M. Hyper-IgE syndromes. Immunol Rev. 2005; 203: 244–250.

14. Brugnoni D., Franceschini F., Airo P., Cattaneo R. Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins. Br J Rheumatol. 1998; 37: 807–808.

15. Min J. K., Cho M. L., Kim S. C. et al. Hyperimmunoglobulin E-recurrent infection syndrome in a patient with juvenile dermatomyositis. Korean J Intern Med. 1999; 14: 95–98.

16. Chang S. E., Huh J., Choi J. H. et al. A case of hyper-IgE syndrome complicated by cutaneous, nodal, and liver peripheral T cell lymphomas. J Dermatol. 2002; 29: 320–322.

17. Onal I. K., Kurt M., Altundag K. et al. Peripheral T-cell lymphoma and Job's syndrome: a rare association. Med Oncol. 2006; 23: 141–144.

18. Yavuz H., Chee R. A review on the vascular features of the hyperimmunoglobulin E syndrome. Clin Exp Immunol. 2010; 159: 238–244.

19. Renner E. D., Rylaarsdam S., Anover-Sombke S. et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T (H) 17 cell numbers, and variably defective

20. STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008; 122 (1): 181–187.

21. Helen Н. C. DOCK8 (Dedicator of cytokinesis 8) deficiency. Curr Opin Allergy Clin Immunol. 2010; 10 (6): 515–520.

22. Freeman A. F., Holland S. M. Clinical manifestations, etiology and pathogenesis of the hyper-IgE syndromes. Pediatr Res.2009; 65: 32–37.

23. Buckley R. H., Schiff S., Sampson H. Reduced frequency of CD45RO+ T lymphocytes in blood of hyper IgE-syndrome patients. J Allergy Clin Immunol. 1991; 87: 313.

24. Dreskin S. C., Goldsmith P. K., StroberW. et al. Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels. J Clin Invest. 1987; 79: 1764–1772.

25. Buckley R. H. The hyper-IgE syndrome. Clin Rev Allergy Immunol. 2001, 20: 139–154.

26. Van Scoy R. E., Hill H. R., Ritts R. E., Quie P. G. Familial neutrophil chemotaxisdefect, recurrent bacterial infections, mucocutaneous candidiasis, and hyperimmunoglobulinemia E. Ann Intern Med. 1975; 82: 766–771.

27. Vercelli D., Jabara H., Cunningham-Rundles C. et al. Regulation of immunoglobulin (Ig) E synthesis in the hyper-IgE syndrome. J Clin Invest. 1990; 85: 1666–1671.

28. Paganelli R., Scala E. Capobianchi M. R. et al. Selective deficiency of interferon-gamma production in the hyper-IgE syndrome. Relationship to in vitro IgE synthesis. Clin Exp Immunol.

29. ; 84: 28–33.

30. Freeman A. F., Holland S. M. Clinical manifestations of hyper IgE syndromes. Dis Markers. 2010; 29 (3–4): 123–30.

31. Minegishi Y., Saito M., Tsuchiya S. et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007; 448: 1058–1062.

32. Holland S. M., DeLeo F. R., Elloumi H. Z. et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007; 357: 1608–1619.

33. Renner E. D., Torgerson T. R., Rylaarsdam S. et al. STAT3 mutation in the original patient with Job's syndrome. N Engl J Med. 2007; 357: 1667–1668.

34. Levy D. E., Lee CK. What does Stat3 do? J Clin Invest. 2002; 109: 1143–1148.

35. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008; 5: 337–348.

36. Kolls J. K., Linden A. Interleukin-17 family members and inflammation. Immunity. 2004; 21: 467–476.

37. Kolls J. K., McCray P. B. Jr., Chan Y. R. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol. 2008; 8: 829–835.

38. Minegishi Y., Karasuyama H. Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency. Curr Opin Allergy Clin Immunol. 2005; 7: 506–509.

39. Minegishi Y., Karasuyama H. Genetic origins of hyper-IgE syndrome. Curr Allergy Asthma Rep. 2008; 8: 386–391.

40. Minegishi Y., Karasuyama H. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int Immunol. 2009; 21: 105–112. Exp Med. 2009 June 8; 206 (6): 1291–1301.

41. Minegishi Y., Saito M., Nagasawa M. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med. 2009; 206 (6): 1291–1301.

42. Milner J. D., Brenchley J. M., Laurence A., Freeman A. F. et al. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008; 452: 773–776.

43. Hawn T. R., Ozinsky A., Williams L. M. et al. Hyper-IgE syndrome is not associated with defects in several candidate toll-like receptor pathway genes. Hum Immunol. 2005; 66: 842–847.

44. Renner E. D., Pawlita I., Hoffmann F. et al. No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome. J Clin Immunol. 2005. Р. 321–328.

45. Engelhardt K. R., McGhee S., Winkler S. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009; 124: 1289–1302.

46. Renner E. D., Rylaarsdam S., Anover-Sombke S. et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T (H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008; 122 (1): 181–7.

47. Lei J. Y., Wang Y., Jaffe E. S. et al. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am J Dermatopathol. 2000; 22 (6): 524–9.

48. Minegishi Y., Saito M., Morio T. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006; 25: 745–755.

49. Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol. 2009; 21 (5): 487–92.

50. Woellner C., Gertz E. M., Schaeffer A. A. et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010; 125: 424–432.

51. Hochreutener H., Wuthrich B., Huwyler T. et al. Variant of hyperIgE syndrome: the differentiation from atopic dermatitis is important because of treatment and prognosis. Dermatologica. 1991; 182: 7–11.

52. Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol. 1995; 95: 771–774.

53. Wakim M., Alazard M., Yajima A. et al. High-dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol. 1998; 81: 153–158.

54. Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадочные синдромы у детей: рекомендации по диагностике и лечению / под общ. ред. А.А. Баранова, В.К. Таточенко, М.Д. Бакрадзе. — М.: Союз педиатров России, 2011. — 228 с.

55. Goussetis E., Peristeri I., Kitra V. et al. Successful longterm immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol. 2010; 126: 392–394.

56. Gatz S. A., Benninghoff U., Schutz C. et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplant. 2011; 46: 552–556.


Для цитирования:


Соботюк Н.В., Потрохова Е.А., Голочалова С.А., Бочанцев С.В., Харламова Т.Н., Стройлова Ю.А. РЕДКИЙ ПЕРВИЧНЫЙ ИММУНОДЕФИЦИТ — ГИПЕР-IGE-СИНДРОМ: ПРЕЗЕНТАЦИЯ СЛУЧАЯ И ОБЗОР ЛИТЕРАТУРЫ. Педиатрическая фармакология. 2013;10(1):54-61. https://doi.org/10.15690/pf.v10i1.589

For citation:


Sobotyuk N.V., Potrokhova E.A., Golochalova S.A., Bochantsev S.V., Kharlamova T.N., Stroylova Y.A. RARE PRIMARY IMMUNODEFICIENCY – HYPER-IgE-SYNDROME: CASE REPORT AND LITERATURE REVIEW. Pediatric pharmacology. 2013;10(1):54-61. (In Russ.) https://doi.org/10.15690/pf.v10i1.589

Просмотров: 533


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)